The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional)
The summary for the The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional): The primary focus of this FOA is to promote studies which apply state-of-the art concepts, technologies, and methodologies in the stem cell field to better understand how stem cells function within diseased or damaged gynecologic tissues. For the purposes of this announcement, the gynecologic disorders of interest are limited to uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. These disorders have been chosen based on their prevalence, high associated morbidity, high branch priority, and substantial costs to the healthcare system. The ultimate goal of this initiative is to improve womens gynecologic health by accelerating our understanding of the role of pluripotent progenitor/stem cells in the initiation, progression and severity of these gynecologic disorders in order to inform the development of effective prevention, diagnostic, and therapeutic strategies.
Federal Grant Title: | The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-HD-20-007 |
Type of Funding: | Grant |
CFDA Numbers: | 93.865 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | September 3rd, 2019 |
Original Application Deadline: | September 3rd, 2019 |
Posted Date: | July 30th, 2019 |
Creation Date: | July 30th, 2019 |
Archive Date: | October 9th, 2019 |
Total Program Funding: | $1,600,000 |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | July 30th, 2019 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-007.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...
- • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...
- • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...
- • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
- • Biological Testing Facility (X01 Clinical Trial Not Allowed)
- • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...
- • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...
- • Reproductive Genetics and Epigenetics
- More Grants from the National Institutes of Health
- • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
- • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...